Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements
Journal of Hematopathology · 2024
DOI: 10.1007/s12308-024-00593-8 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Hematopathology, 2024. Verfasst von Fnu Monika und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Creighton University, Omaha, NE, 68124, USA. monika@creighton.edu. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-6, Cyclin D1, Proto-Oncogene Proteins c-bcl-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Quadruple-hit lymphomas are extremely rare non-Hodgkin lymphomas with a reported dismal prognosis in the few reported cases. A “quadruple hit” has been defined by the presence of concurrent MYC , BCL2 , BCL6 , and CCND1 chromosomal rearrangements . We report a new case of a quadruple hit lymphoma in a 73-year-old Hispanic man who presented with an enlarging left-sided neck mass. Computed tomography showed a 1.9-cm mass in left the tonsil with bulky cervical lymphadenopathy. The presence of all four chromosomal rearrangements can reportedly occur with disease progression in both diffuse large B-cell lymphomas and mantle cell lymphomas. Further characterization of the tumor by next-generation sequencing may be of benefit to delineate between these two possibilities. Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and next-generation sequencing were used to confirm and classify the diagnosis. Histologic sections of the cervical lymph node demonstrated an atypical lymphoid infiltrate with large and pleomorphic cells, which were positive for CD20, CD10, BCL1 (Cyclin D1), BCL2, BCL6, and cMYC and negative for CD5 and SOX11 on immunohistochemistry with a Ki-67 proliferative index of 70%. FISH demonstrated MYC , BCL2 , BCL6 , and CCND1 rearrangements and the diagnosis of high-grade B-cell lymphoma with MYC , BCL2 , BCL6 , and CCND1 was rendered. Our patient was treated with dose adjusted etoposide, doxorubicin, cyclophosphamide, prednisone, and rituximab chemotherapy and has been in remission for 20 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Creighton University, Omaha, NE, 68124, USA. monika@creighton.edu.
- Department of Pathology, Creighton University, Omaha, NE, 68124, USA.
- Department of Pathology, CHI Health Creighton University, Omaha, NE, 68124, USA.
- Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Zitieren
APA
Monika, F., Sabri, A., Cantu, D., Vail, E., & Siref, A. (2024). Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements. Journal of Hematopathology. https://doi.org/10.1007/s12308-024-00593-8
Vancouver
Monika F, Sabri A, Cantu D, Vail E, Siref A. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements. Journal of Hematopathology. 2024. doi:10.1007/s12308-024-00593-8
BibTeX
@article{Monika2024,
author = {Monika, Fnu and Sabri, Ahmed and Cantu, David and Vail, Eric and Siref, Andrew},
title = {Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements},
journal = {Journal of Hematopathology},
year = {2024},
doi = {10.1007/s12308-024-00593-8}
}
EUVIMED